within Pharmacolibrary.Drugs.ATC.C;

model C03AB04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.09,
    Cl             = 0.004,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C03AB04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Chlorothiazide and potassium is a combination medication used as a diuretic to treat hypertension, congestive heart failure, and edema by promoting the excretion of sodium and water, while potassium is added to counteract potential hypokalemia caused by the diuretic. Chlorothiazide is a thiazide diuretic, and potassium supplementation helps prevent electrolyte imbalance. This combination may still be prescribed, though fixed-dose combinations are less common today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adults, as published PK models for the combination product are unavailable. Estimates are based on known PK parameters of chlorothiazide component administered orally.</p><h4>References</h4><ol><li><p>Maronde, RF, et al., &amp; Chan, L (1984). Oral potassium chloride and amiloride in hydrochlorothiazide-induced potassium loss. <i>Clinical pharmacology and therapeutics</i> 36(4) 431–435. DOI:<a href=&quot;https://doi.org/10.1038/clpt.1984.200&quot;>10.1038/clpt.1984.200</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6478730/&quot;>https://pubmed.ncbi.nlm.nih.gov/6478730</a></p></li><li><p>McNeil, JJ, et al., &amp; Louis, WJ (1987). Clopamide: plasma concentrations and diuretic effect in humans. <i>Clinical pharmacology and therapeutics</i> 42(3) 299–304. DOI:<a href=&quot;https://doi.org/10.1038/clpt.1987.151&quot;>10.1038/clpt.1987.151</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3621784/&quot;>https://pubmed.ncbi.nlm.nih.gov/3621784</a></p></li><li><p>Nagashima, K, et al., &amp; Karasawa, A (1995). Protective effects of KW-3902, an adenosine A1-receptor antagonist, against cisplatin-induced acute renal failure in rats. <i>Japanese journal of pharmacology</i> 67(4) 349–357. DOI:<a href=&quot;https://doi.org/10.1254/jjp.67.349&quot;>10.1254/jjp.67.349</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7650867/&quot;>https://pubmed.ncbi.nlm.nih.gov/7650867</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C03AB04;
